Multiple Interactions between Peroxisome Proliferators-Activated Receptors and the Ubiquitin- Proteasome System and Implications for Cancer Pathogenesis

被引:26
作者
Genini, Davide [1 ]
Carbone, Giuseppina M. [1 ]
Catapano, Carlo V. [1 ]
机构
[1] Oncol Inst So Switzerland IOSI, Expt Oncol Lab, CH-6500 Bellinzona, Switzerland
关键词
D O I
10.1155/2008/195065
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The peroxisome proliferator-activated receptors (PPAR) alpha, beta/delta, and gamma are ligand-activated nuclear receptors involved in a number of physiological processes, including lipid and glucose homeostasis, inflammation, cell growth, differentiation, and death. PPAR agonists are used in the treatment of human diseases, like type 2 diabetes and dyslipidemia, and PPARs appear as promising therapeutic targets in other conditions, including cancer. A better understanding of the functions and regulation of PPARs in normal and pathological processes is of primary importance to devise appropriate therapeutic strategies. The ubiquitin-proteasome system (UPS) plays an important role in controlling level and activity of many nuclear receptors and transcription factors. PPARs are subjected to UPS-dependent regulation. Interestingly, the three PPAR isotypes are differentially regulated by the UPS in response to ligand-dependent activation, a phenomenon that may be intrinsically connected to their distinct cellular functions and behaviors. In addition to their effects ongene expression, PPARs appear to affect protein levels and downstream pathways also by modulating the activity of the UPS in target-specific manners. Here we review the current knowledge of the interactions between the UPS and PPARs in light of the potential implications for their effects on cell fate and tumorigenesis. Copyright (C) 2008 Davide Genini et al.
引用
收藏
页数:11
相关论文
共 101 条
[1]   Transcriptional network governing the angiogenic, switch in human pancreatic cancer [J].
Abdollahi, Amir ;
Schwager, Christian ;
Kleeff, Joerg ;
Esposito, Irene ;
Domhan, Sophie ;
Peschke, Peter ;
Hauser, Kai ;
Hahnfeldt, Philip ;
Hlatky, Lynn ;
Debus, Juergen ;
Peters, Jeffrey M. ;
Friess, Helmut ;
Folkman, Judah ;
Huber, Peter E. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (31) :12890-12895
[2]   The proteasome: A suitable antineoplastic target [J].
Adams, J .
NATURE REVIEWS CANCER, 2004, 4 (05) :349-360
[3]   Nuclear hormone receptors and gene expression [J].
Aranda, A ;
Pascual, A .
PHYSIOLOGICAL REVIEWS, 2001, 81 (03) :1269-1304
[4]  
Baek KH, 2003, EXP MOL MED, V35, P1
[5]   PPARδ:: a dagger in the heart of the metabolic syndrome [J].
Barish, GD ;
Narkar, VA ;
Evans, RM .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (03) :590-597
[6]   Different ways to regulate the PPARα stability [J].
Blanquart, C ;
Mansouri, R ;
Fruchart, JC ;
Staels, B ;
Glineur, C .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 319 (02) :663-670
[7]   Peroxisome proliferator-activated receptor α (PPARα) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes [J].
Blanquart, C ;
Barbier, O ;
Fruchart, JC ;
Staels, B ;
Glineur, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (40) :37254-37259
[8]   Deregulated degradation of the cdk inhibitor p27 and malignant transformation [J].
Bloom, J ;
Pagano, M .
SEMINARS IN CANCER BIOLOGY, 2003, 13 (01) :41-47
[9]   Modulation of PPAR activity via phosphorylation [J].
Burns, Katherine A. ;
Vanden Heuvel, John P. .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2007, 1771 (08) :952-960
[10]   SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 [J].
Carrano, AC ;
Eytan, E ;
Hershko, A ;
Pagano, M .
NATURE CELL BIOLOGY, 1999, 1 (04) :193-199